Xavier Gitton

2.6k citations

22 papers · 1.9k indexed · 1 hit paper · h-index 14

Pharmacology top 0.5%
- Inflammatory mediators and NSAID effects 13
Biochemistry top 2%
- Eicosanoids and Hypertension Pharmacology 4
Hematology top 5%
- Autoimmune and Inflammatory Disorders Research 2
Rheumatology top 5%
- Osteoarthritis Treatment and Mechanisms 4
Cardiology and Cardiovascular Medicine top 5%
- Antiplatelet Therapy and Cardiovascular Diseases 9
Molecular Biology
- Inflammasome and immune disorders 2
Parasitology
- Leptospirosis research and findings 2
Organic Chemistry
- Synthesis of β-Lactam Compounds 2

Co-authors: Gerhard Krammer A. Widmer Christopher J. Hawkey Thomas J. Schnitzer B. Mellein Patrice Matchaba Pierre Quartier Jasmin Kuemmerle‐Deschner
Cited by: Pharmacology Biochemistry Hematology
Journals: Veterinary Microbiology (2 papers)The Lancet (2 papers)Gastroenterology (2 papers)
Partner nations: Switzerland United States United Kingdom

In The Last Decade

Xavier Gitton

22 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Xavier Gitton

Since Specialization

Citations

This map shows the geographic impact of Xavier Gitton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Gitton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Gitton more than expected).

Fields of papers citing papers by Xavier Gitton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Gitton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Gitton. The network helps show where Xavier Gitton may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Xavier Gitton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xavier Gitton Line = papers co-authored together Xavier Gitton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER‐MRI studies Pulmonary Circulation ·Allan Lawrie,Kelly Chin,Y L Fong,Cynthia Gargano,Xavier Gitton,Cheng He,David G. Kiely,D. de Zwart,Lihan Zhou,Bradley A. Maron,三好晃治,Stephan Rosenkranz,V. P. Lazurko,Mark Toshner,Martin R. Wilkins,Luke Howard,Ioana R. Preston	2024	2
2	Electrocardiogram Detection of Pulmonary Hypertension Using Deep Learning Journal of Cardiac Failure ·Mandar A. Aras,Sean Abreau,Wu Pei Tian,Lakshmi Radhakrishnan,Liviu Klein,任学才,B. A. Rubin,Joshua Barrios,Christel Chehoud,Zhe Sun,Xavier Gitton,Tanya M. Johnson,Deborah A. Quinn,Charles R. Bridges,Atul J. Butte,Jeffrey E. Olgin,Geoffrey H. Tison	2023	17
3	Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study BMC Musculoskeletal Disorders ·Rieke Alten,Juan J. Gómez‐Reino,Patrick Durez,André Beaulieu,Anthony Sebba,Gerhard Krammer,Ralph Preiss,Udayasankar Arulmani,A. Widmer,Xavier Gitton,Herbert Kellner	2011	114
4	Patient flow diagram Figshare ·Maxime Dougados,Alan Moore,Shaohua Yu,Xavier Gitton	2011	2
5	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndromebreakdown → New England Journal of Medicine ·Helen J. Lachmann,Isabelle Koné‐Paut,Jasmin Kuemmerle‐Deschner,Kieron Leslie,É. Hachulla,Pierre Quartier,Xavier Gitton,A. Widmer,Pavlo Breus,Philip N. Hawkins	2009	627
6	Efficacy and Safety of Canakinumab (ACZ885), a Fully Human Anti-Interleukin-1b-Antibody, in Cryopyrin Associated Periodic Fever Syndrome Results of a Multicenter, Randomized, Double-blind, Phase III Study Journal of Allergy and Clinical Immunology ·Herbert M. Lachman,Isabelle Koné‐Paut,Jasmin Kuemmerle‐Deschner,T.S. Goreva,É. Hachulla,Pierre Quartier,Xavier Gitton,Nidhi Patel,K. Lheritier,Philip N. Hawkins	2009	1
7	A Comparison of the Blood Pressure Changes of Lumiracoxib With Those of Ibuprofen and Naproxen Journal of Clinical Hypertension ·Michael E. Farkouh,Freek W.A. Verheugt,Sean Ruland,Howard S. Kirshner,Raban Jeger,Xavier Gitton,Gerhard Krammer,Kirstin Stricker,Peter Sallstig,B. Mellein,Patrice Matchaba,James H. Chesebro	2008	5
8	Efficacy and Tolerability of Lumiracoxib 200 mg Once Daily for Treatment of Primary Dysmenorrhea: Results from Two Randomized Controlled Trials Journal of Women s Health ·Stephen Daniels,Xavier Gitton,Alberto G Monsalve,Kirstin Stricker,Wobbes	2008	16
9	Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study Gastroenterology ·Christopher J. Hawkey,Wilfred M. Weinstein,Walter Smalley,Xavier Gitton,Peter Sallstig,Kirstin Stricker,Gerhard Krammer,B. Mellein,Dominik Richard,Patrice Matchaba	2007	17
10	Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis Arthritis Research & Therapy ·Maxime Dougados,Alan Moore,Shaohua Yu,Xavier Gitton	2007	39
11	Gastrointestinal Tolerability of Lumiracoxib in Patients With Osteoarthritis and Rheumatoid Arthritis Clinical Gastroenterology and Hepatology ·Christopher J. Hawkey,Xavier Gitton,R. Holdaway,Dominik Richard,Wilfred M. Weinstein	2006	11
12	Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies Current Medical Research and Opinion ·Thomas J. Schnitzer,James R. Fricke,Xavier Gitton,Stephanie Edwards,Victor S. Sloan	2005	17
13	Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis Clinical Therapeutics ·Patrice Matchaba,Xavier Gitton,Gerhard Krammer,Putri Astari Makki,Victor S. Sloan,Melvin Olson,B. Mellein,R. Holdaway,John J. Orloff,Jean–Jacques Garaud	2005	44
14	Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial The Lancet ·Thomas J. Schnitzer,Gerd R Burmester,Eduardo Mysler,Marc C. Hochberg,Michael Doherty,Putri Astari Makki,Xavier Gitton,Gerhard Krammer,B. Mellein,Patrice Matchaba,Alberto Gimona,Christopher J. Hawkey	2004	493
15	Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics Alimentary Pharmacology & Therapeutics ·Christopher J. Hawkey,Michael E. Farkouh,Xavier Gitton,Putri Astari Makki,Jasper Huels,Peter Richardson	2004	26
16	Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial The Lancet ·Michael E. Farkouh,Howard S. Kirshner,Robert A. Harrington,Sean Ruland,Freek W.A. Verheugt,Thomas J. Schnitzer,Gerd R Burmester,Eduardo Mysler,Marc C. Hochberg,Michael Doherty,Putri Astari Makki,Xavier Gitton,Gerhard Krammer,B. Mellein,Alberto Gimona,Patrice Matchaba,Christopher J. Hawkey,James H. Chesebro	2004	364
17	Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four‐week, multicenter, randomized, double‐blind, placebo‐controlled trial Arthritis Care & Research ·Thomas J. Schnitzer,MARIA JOSÉ VELIZ MAYORGA,Piet Geusens,Paul Hasler,Sanjay K. S. Patel,Filipe Eduard Leite Ossege,Xavier Gitton,Alan Moore,Victor S. Sloan,Gyula Poór	2004	46
18	The gastrointestinal tolerability of a novel COX-2 selective inhibitor, lumiracoxb, in osteoarthritis patients: Pooled analysis Gastroenterology ·Christopher J. Hawkey,Xavier Gitton,Alberto Gimona,R. Holdaway,Wilfred M. Weinstein	2003	2
19	Recognition of Leptospira interrogans antigens by vaccinated or infected dogs Veterinary Microbiology ·Xavier Gitton,Chung Pei-Chen,Fabrice André,Jean‐Pierre Ganière,G. André‐Fontaine	1994	18
20	Immunoblotting study of the antigenic relationships among eight serogroups of Leptospira Veterinary Microbiology ·Xavier Gitton,Scott Hoffman,Andreas Stein,Jean‐Pierre Ganière	1992	12

About Xavier Gitton

Xavier Gitton is a scholar working on Pharmacology, Biochemistry, Cardiology and Cardiovascular Medicine, Rheumatology and Parasitology, having authored 22 papers that have together received 1.9k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (13 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers), Eicosanoids and Hypertension Pharmacology (4 papers), Osteoarthritis Treatment and Mechanisms (4 papers), Autoimmune and Inflammatory Disorders Research (2 papers), Inflammasome and immune disorders (2 papers), Leptospirosis research and findings (2 papers) and Synthesis of β-Lactam Compounds (2 papers). The work is most often cited by research in Pharmacology (966 citations), Biochemistry (226 citations), Hematology (266 citations), Rheumatology (325 citations) and Cardiology and Cardiovascular Medicine (428 citations). Xavier Gitton has collaborated with scholars based in Switzerland, United States and United Kingdom. Frequent co-authors include Gerhard Krammer, A. Widmer, Christopher J. Hawkey, Thomas J. Schnitzer, B. Mellein, Patrice Matchaba, Pierre Quartier, Jasmin Kuemmerle‐Deschner, É. Hachulla and Kieron Leslie. Their work appears in journals such as Veterinary Microbiology, The Lancet, Gastroenterology, Alimentary Pharmacology & Therapeutics and Journal of Allergy and Clinical Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact